



Date: 16 January 2020

Sydney, Australia

ASX Limited
20 Bridge Street
SYDNEY NSW 2000

Listing of Nyrada Inc. spin-off on ASX

- IPO offer fully subscribed raising \$8.5M
 - Focus on non-oncology areas of significant large and unmet needs
 - NOX to remain a major shareholder post-IPO with 2 Board nominees
 - Equity in Nyrada now a major asset for NOX
-

Sydney, 16 January 2020: Noxopharm (ASX: NOX) announces the listing today on the ASX (ASX: NYR) of its spin-off company, Nyrada Inc (Nyrada).

The IPO Offer was fully subscribed, with A\$8.5M being raised.

Nyrada is a U.S.-registered company, listing on the ASX as a foreign entity. Accordingly, its securities will trade as CHESS Depositary Interests (CDIs).

- On a fully diluted basis, Noxopharm post-listing will hold 26.9% shareholding in Nyrada. 7.1% of this shareholding is in the form of performance shares bearing the milestone of assets becoming clinic-ready.
- Noxopharm is represented on the Nyrada Board by Graham Kelly and Peter Marks, both of whom will serve as Non-Executive Directors.

Nyrada was established in 2017 to advance the non-oncology assets developed by Noxopharm, leaving Noxopharm free to concentrate on the development of Veyonda[®]. Nyrada commenced with three drug assets transferred from Noxopharm. It then acquired a fourth asset through the purchase of an external private company. The four Nyrada drug programs are seeking the development of:

- An oral PCSK9 inhibitor to assist in the lowering of LDL cholesterol in patients where statin therapy is inadequate
- A neuroprotectant to reduce secondary brain damage and long-term disability following stroke or traumatic brain injury
- A drug to reduce inflammation and pain in peripheral nerves associated with crush injury (eg. sciatica) and chemical injury (eg. chemotherapy)



- A drug to reduce chronic inflammation leading to autoimmune diseases including psoriasis and multiple sclerosis.

Graham Kelly, Noxopharm CEO and Executive Chairman, said, “Both companies now are completely functionally and financially independent of each other, although the intention is that they will continue to cooperate closely for the immediate future as a result of significant cross-over between their respective assets. I see this symbiotic relationship as one of the great strengths of this IPO, effectively doubling the development and discovery opportunities for both companies.”

About Noxopharm

Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.

www.noxopharm.com

Ends

.....
This announcement has been approved and authorised for release by Dr Graham Kelly, Noxopharm CEO, by authority of the Noxopharm Board.

Investor & Corporate Enquiries:

Prue Kelly
T: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@atomicgroup.com.au

Media Enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com



Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.